Alnylam Pharmaceuticals
ALNY
#558
Rank
NZ$63.91 B
Marketcap
$490.20
Share price
2.57%
Change (1 day)
103.97%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): -$3.23

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$3.28. In 2023 the company made an earnings per share (EPS) of -$5.91 an increase over its 2022 EPS that were of -$15.55.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)-$3.23
2023-$5.91-62%
2022-$15.5529.03%
2021-$12.05-3.36%
2020-$12.47-8.48%
2019-$13.627.67%
2018-$12.6539.74%
2017-$9.0512.94%
2016-$8.0238.84%
2015-$5.77-32.88%
2014-$8.60259.44%
2013-$2.39-31.25%
2012-$3.48

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.69-48.47%๐Ÿ‡บ๐Ÿ‡ธ USA
$69.89-2,230.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.23 29.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.08368-97.45%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.22-62.76%๐Ÿ‡บ๐Ÿ‡ธ USA
$10.76-428.06%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.77-245.49%๐Ÿ‡ซ๐Ÿ‡ท France
-$1.91-41.84%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel